Phase 1 trial of ACT-017 for the treatment of Acute Ischemic Stroke
Phase of Trial: Phase I
Latest Information Update: 17 Oct 2017
At a glance
- Drugs ACT 017 (Primary)
- Indications Stroke
- Focus Adverse reactions; First in man
- 17 Oct 2017 According to an Acticor Biotech media release, the results of this study are expected for Q1 2018, and will be used to determine the appropriate ACT017 dosage for phase II studies. The first cohort of volunteers will be enrolled by the end of October 2017.
- 17 Oct 2017 Status changed from planning to recruiting, according to an Acticor Biotech media release.
- 19 May 2017 According to an Acticor Biotech media release, the company is planning to initiate this trial in October 2017 and to end in January 2018.